Meghan Mallett, APRN
Family · Conway, ARNPI 1295193191
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,907 of the $25,227 with a category attached, or 94.8%. Insulet Corporation accounts for 96.5% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $17,756, more than ten times the $171 reported in 2021. Among family clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 98 payments — averaging $257.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$24K
- Abbott$123
- Lilly USA, LLC$113
- GSK$101
- Pfizer$101
- Novo Nordisk$82
- plus $356 from 10 others
What the payments were for
- Speaking & faculty fees$23,90795%
- Travel & lodging$3862%
- Food & beverage$9344%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 47 | $24,351 |
| Abbott | 7 | $123 |
| Lilly USA, LLC | 7 | $113 |
| GSK | 6 | $101 |
| Pfizer | 5 | $101 |
| Novo Nordisk | 5 | $82 |
| Boehringer Ingelheim | 4 | $81 |
| AstraZeneca | 5 | $75 |
| Dexcom, Inc. | 3 | $53 |
| Amgen | 2 | $34 |
| AbbVie | 2 | $31 |
| Astellas Pharma US Inc | 1 | $25 |
| Exact Sciences | 1 | $16 |
| Phadia US Inc. | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$23,907
How this compares
$25,227 in reported general payments places this provider in the 95th percentile of 2,103 family providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 163 | $187,885 |
| JardianceEmpagliflozin | 101 | $104,864 |
| MounjaroTirzepatide | 69 | $78,893 |
| EliquisApixaban | 83 | $57,209 |
| FarxigaDapagliflozin Propanediol | 34 | $33,248 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $24,076 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 19 | $16,137 |
| TrulicityDulaglutide | 12 | $14,327 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 34 | $11,099 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 11 | $6,843 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $6,751 |
| Duloxetine Hcl | 185 | $3,832 |
| Atorvastatin Calcium | 411 | $3,556 |
| Levothyroxine Sodium | 304 | $2,984 |
| Tolterodine Tartrate ErTolterodine Tartrate | 11 | $2,681 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $82 | $187,885163 claims |
| Boehringer IngelheimJardiance | $81 | $104,864101 claims |
| Lilly USA, LLCMounjaro, Trulicity | $113 | $93,22081 claims |
| PfizerEliquis | $101 | $57,20983 claims |
| AstraZenecaFarxiga | $75 | $33,24834 claims |
| GSKTrelegy Ellipta | $101 | $24,07636 claims |
| AbbVieSynthroid | $31 | $1,32622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,103 family providers in Arkansas.
Other family in Conway
- Sheila ForresterConway$17K
- Elana RussellConway$17K
- Donald KulbethConway$12K
- Kayla JohnsonConway$9K
- Crystal BrownConway$9K
- Leah CarringtonRogers$1.6M
- Nina CopelandFort Smith$207K
- Stefanie BrackinJonesboro$51K
- Amanda DavisFort Smith$46K
- Allison HittManila$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.